Dose range
0.3 → 2.4 mg/wk
Route
Subcutaneous injection, once weekly
Indication(s)
Long-acting amylin analog; co-formulation with sema (CagriSema) in trials

Titration schedule

StepDoseDurationNotes
10.3 mg/weekWeeks 1-4Investigational
20.6 mg/weekWeeks 5-8
31.2 mg/weekWeeks 9-12
42.4 mg/weekWeek 13+CagriSema combo trial dose

Important notes

  • This research compound dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
  • Research compound; not FDA-approved for any indication. Off-label or experimental use only.
  • Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.

References

  1. Cagrilintide (investigational) prescribing information / clinical literature.
  2. FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
  3. USP <797>: Pharmaceutical Compounding — Sterile Preparations.